EDIT Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Zacks Investment Research - Mentions: BEAM

Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?

14 days ago - By: The Motley Fool

Editas (EDIT) Q2 2024 Earnings Call Transcript

20 days ago - By: Zacks Investment Research - Mentions: AZN MRK ADMA

AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo

21 days ago - By: Zacks Investment Research - Mentions: ADMA COGT ARQT

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know

23 days ago - By: Zacks Investment Research - Mentions: ILMN PACB NTLA CRSP ...

Top 3 Genomics Stocks to Consider for Your Portfolio

a month ago - By: Zacks Investment Research - Mentions: ANRO

Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year?

3 months ago - By: Benzinga

Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

a month ago - By: Zacks Investment Research - Mentions: ANIP ADMA ARQT

Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y

a month ago - By: Zacks Investment Research - Mentions: DARE

Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates

a month ago - By: Editas Medicine, Inc.

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

a month ago - By: Editas Medicine, Inc.

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

a month ago - By: Zacks Investment Research - Mentions: JANX

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates

a month ago - By: Editas Medicine, Inc.

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

2 months ago - By: Benzinga - Mentions: XBI ALNY IBB NTLA ...

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles

2 months ago - By: Editas Medicine, Inc.

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

2 months ago - By: Editas Medicine, Inc.

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

2 months ago - By: Editas Medicine, Inc.

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

2 months ago - By: Editas Medicine, Inc.

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

3 months ago - By: Zacks Investment Research - Mentions: CRMD KNSA PHAR

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

3 months ago - By: Editas Medicine, Inc.

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

3 months ago - By: Editas Medicine, Inc.

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

4 months ago - By: Editas Medicine, Inc.

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

4 months ago - By: Editas Medicine, Inc.

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

4 months ago - By: Editas Medicine, Inc.

Editas Medicine to Participate in Upcoming Investor Conferences

4 months ago - By: Editas Medicine, Inc.

Editas Medicine to Participate in Upcoming Investor Conferences

4 months ago - By: The Motley Fool

Why Editas Medicine Stock Was Skyrocketing This Week

4 months ago - By: Zacks Investment Research - Mentions: DARE

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Editas Medicine, Inc.

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

4 months ago - By: Editas Medicine, Inc.

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

4 months ago - By: Zacks Investment Research - Mentions: TCRX

EDITAS MEDICINE INC (EDIT) Stock News

EDIT Latest News, Press Relases and Analysis

Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?

Editas (EDIT) Q2 2024 Earnings Call Transcript

AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know

Top 3 Genomics Stocks to Consider for Your Portfolio

Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year?

Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y

Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine to Participate in Upcoming Investor Conferences

Why Editas Medicine Stock Was Skyrocketing This Week

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates